Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer

Urology

Volumn 50, Issue 6, 1997, Pages 1007-1015

  Balaji, K C ^b   Koul, Hari ^b   Mitra, Sankar ^b   Maramag, Carlos ^b   Reddy, Premveer ^b   Menon, Mani ^b   Malhotra, Rajwant Kaur ^b   Laxmanan, Seethalaksmi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL VIABILITY; DNA CONTENT; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER;

ANALYSIS OF VARIANCE; AUTORADIOGRAPHY; CELL DIVISION; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENES, MYC; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031464069     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00390-7     Document Type: Article

References (31)

1. Wolf DA, Kohlhuber F, Schultz P, Fittler F, and Eick D: Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone. Br J Cancer 65: 376-382, 1992.
2. Campisi J, Gray HE, Pardee AB, Dean M, and Sonenshen GE: Cell cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell 36: 241-247, 1984.
3. Steiner MS, Satterwhite DJ, and Moses HL: Molecular insights into altered cell cycle regulation and genitourinary malignancy. Urol Oncol 1: 3-17, 1995.
4. Thompson C, Challoner PB, Neiman PE, and Groudine M: Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature 314: 363-366, 1985.
5. Spencer CA, and Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56: 1-48, 1991.
6. Kelly K, Cochran BH, Stiles CD, and Leder P: Cell specific regulation of c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35(3 pt 2): 603-610, 1983.
7. Prins J, De Vries EGE, and Mulder NH: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 13: 1373-1385, 1993.
8. Huncharek M, and Muscat J: Genetic characteristics of prostate cancer. Cancer Epidimiol Biomarkers Prev 4: 681-687, 1995.
9. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer Statistics, 1996. CA Cancer J Clin 46: 1, 1996.
10. Calabretta B: Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 51: 4505-4510, 1991.
11. Schuurmans AL, Bolt J, Veldscholte J, and Mulder E: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 37: 849-853, 1990.
12. Kaighn ME, Narayan KS, Ohnuki T, Lechner JF, and Jones LW: Establishment and characterization of a human prostatic cell line (PC3). Invest Urol 17: 16-23, 1979.
13. Micky DD, Stone KR, Wunderli H, Mickey GH, and Paulson DF: Characterization of a human adenocarcinoma cell line (DU145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res 37: 64-84, 1980.
14. Kislauskis EH, Zhu X, and Singer RH: Sequences responsible for intracellular localization of beta-actin messenger RNA also affect cell phenotype. J Cell Biol 127: 441-451, 1994.
15. Watson PH, Pon RT, and Shiu RP: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996-4000, 1991.
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
17. Koul H, Kennington L, Nair G, Honeyman T, Menon M, and Scheid C: Oxalate induced initiation of DNA synthesis in LLC-PK1 cells, a line of renal epithelial cells. Biochem Biophys Res Commun 205: 1632-1637, 1994.
18. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Holz MA, Lassota P, and Tragaros F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
19. Keyomarsi K, Sandoval L, Band V, and Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
20. Reddy GPV: Catalytic function of thymidylate synthase is confined to S phase due to its association with replitase. Biochem Biophys Res Commun 109: 908-915, 1982.
21. Reddy GPV, and Pardee AB: Inhibitor evidence for allosteric interaction in the replitase multienzyme complex. Nature 304: 86-88, 1983.
22. Heufelder AE, and Bahn RS: Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene. Invest Ophthalmol Vis Sci 36: 1420-1432, 1995.
23. Paria BC, Dey SK, and Andrews GK: Antisense c-myc effects on preimplantation mouse embryo development. Proc Natl Acad Sci USA 89: 10051-10055, 1992.
24. Buttyan R, Sawczuk IS, Benson M, Siegal JD, and Olsson CA: Enhanced expression of the c-myc protooncogene in high grade human prostate cancers. Prostate 11: 327-337, 1987.
25. Peehl DM: Oncogenes in prostate cancer. An update. Cancer 71(3 suppl) 1159-1164, 1993.
26. Kimura S, Maekawa T, Hirakawa K, Murakami A, and Abe T: Alterations of c-myc expression by antisense oligonucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 55: 1379-1384, 1995.
27. Dosaka-Akita H, Akie K, Hiroumi H, Kinoshita I, Kawakami Y, and Murakami A: Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res 55: 1559-1564, 1995.
28. Collins JF, Herman P, Schuch C, and Bagby GC Jr: c-myc antisense oligonucleotides inhibit the colony forming capacity of Colo 320 colonic carcinoma cells. J Clin Invest 89: 1523-1527, 1992.
29. Wu HC, Hsieh JT, Cleave ME, Brown NM, Pathak S, and Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-412, 1994.
30. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci USA 92: 4051-4055, 1995.
31. Chavany C, Connell Y, and Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48: 738-746, 1995.